Delivery Order SPE2DB24D3013-SPE2DB25FFQBB
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $8,894.37 to AmerisourceBergen Drug Corp for TALTZ 80 MG/ML Autoinjector on August 25, 2025, with completion scheduled for August 26, 2025. This competitive award, utilizing firm fixed pricing with no set-aside designation, represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a $21,972.38 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of TALTZ 80 mg/mL autoinjectors. This firm fixed-price delivery order, which is expected to be completed by August 25, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside...
- The Defense Logistics Agency awarded a $22,497.98 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for TALTZ 80 mg/ml autoinjector supply. This is a firm fixed price, non-set-aside contract with a completion date of August 15, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $23,302.89 to AmerisourceBergen Drug Corp for TALTZ 80 mg/mL AutoInjector on August 18, 2025, with an ultimate completion date of August 19, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. TALTZ is a biologic medication used to treat inflammatory conditions, and this...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of TALTZ 80 mg/ml auto-injector two-packs with a ceiling value of $8,391.13. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a $6,641.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml autoinjector, a pharmaceutical product used in the treatment of autoimmune conditions. The contract was awarded on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively procured with no set-aside designation. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $28,410.76 to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml autoinjector, a pharmaceutical product used in the treatment of autoimmune conditions. This firm fixed price delivery order, with an ultimate completion date of August 21, 2025, was awarded on August 20, 2025, with no set-aside designation. The contract represents a competitive award under AmerisourceBergen's larger federal contracting relationship with DLA and reflects...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Taltz 80 mg/ml autoinjector medication with a ceiling value of $17,030.96. This firm fixed-price delivery order, which is set to conclude on August 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $36,879.90 firm fixed-price delivery order is for the supply of TALTZ 80 MG/ML AUTOINJECTORML, a specialty medication. The contract has an ultimate completion date of January 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
- The Defense Logistics Agency (DLA) awarded a $31,833.56 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/mL auto-injector (2-pack) pharmaceutical products, with an ultimate completion date of July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFQBBDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $17,287.82 by the Defense Logistics Agency (DLA) on September 2, 2025, for the supply of TALTZ 80 mg/ml autoinjector medication. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of September 3, 2025, and performance based in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling value and extends through December 2026. TALTZ (ixekizumab) is a biologic immunosuppressant used to treat autoimmune and inflammatory conditions. This delivery order exemplifies AmerisourceBergen's role as a critical pharmaceutical distributor within the federal medical supply chain, leveraging its comprehensive prime vendor agreement with DLA to fulfill specialty medication requirements for military and veteran healthcare systems. The contract was competitively awarded through open competition, consistent with AmerisourceBergen's established pattern of federal pharmaceutical procurement contracts across multiple therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.3k | 9/2/25 |